What question did this study set out to answer?

The study aims to analyze OCT4 expression as a biomarker in pancreatic adenocarcinoma (PDAC) and its implications for cancer progression.

March 26, 2026

View Full Paper

Immunocytochemical Analysis of Stem Cell Markers in Pancreatic Adenocarcinoma

Key Points

The study aims to analyze OCT4 expression as a biomarker in pancreatic adenocarcinoma (PDAC) and its implications for cancer progression.
Immunocytochemical analysis of stem cell markers in pancreatic adenocarcinoma samples.
Assessment of OCT4 expression levels and correlation with PDAC progression.
Evaluation of CD24 activation status in relation to OCT4 expression.
Higher OCT4 expression correlates with PDAC progression.
CD24 activation is observed in a subset of PDAC with increased OCT4 levels.
KRAS mutant PDAC cases show lower OCT4 expression compared to non-mutant cases, suggesting different progression mechanisms.

Abstract

OCT4 expression is a specific biomarker for PDAC. Its increased expression signified PDAC progression and CD24 activation in a subset of PDAC. KRAS mutants have lower OCT4 expression, suggesting an alternative mechanism for cancer progression than that in OCT4 positive PDAC.

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Al‐Temaimi et al. (Mon,) studied this question.

synapsesocial.com/papers/69c4cd8dfdc3bde44891a071 https://doi.org/https://doi.org/10.1111/cyt.70072

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Demander à l'IA

Bookmark

View Full Paper